TiGenix : presenting at 15th Annual BIO CEO & Investor Conference
february 12, 2013
TiGenix to present at 15(th) Annual BIO CEO & Investor Conference
Leuven (BELGIUM) - February 12, 2013 - TiGenix (NYSE Euronext: TIG), a leader in
the field of cell therapy, announced today that Eduardo Bravo, CEO, will be
presenting at the 15th Annual BIO CEO & Investor Conference. Hosted by the
Biotechnology Industry Organization (BIO), the 15th Annual BIO CEO & Investor
Conference will take place February 11-12 at the Waldorf Astoria in New York
City.
Presentation Details:
Date & time: Â Â Â Â Â Â Â Â Â Â Â Â Â Tuesday, February 12, 8:30 - 8:55 AM EST
Presenter: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Eduardo Bravo, CEO
Location: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Conrad Room
Click here for access to live webcast (registration free, but required)
Replay available 1 hour after live event; archived webcast expires May 12, 2013
About TiGenix
TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company
with a marketed product for cartilage repair, ChondroCelect®, and a strong
pipeline with clinical stage allogeneic adult stem cell programs for the
treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the
Netherlands). For more information please visit www.tigenix.com.
About the BIO CEO & Investor Conference
The 15th Annual BIO CEO & Investor Conference is the largest independent
investor conference focused on publicly-traded biotechnology companies. This
year's conference will feature corporate presentations from more than 150
leading biotechnology and pharmaceutical companies, five Fireside Chats with
industry leaders, three Therapeutic Workshops and five Business Roundtables all
drawing from seasoned industry executives and analysts. New this year, a special
track of 25 high-caliber private companies will be presenting at the event, and
plenary sessions will address timely business issues and industry trends.
Attendees can expect many opportunities to schedule one-on-one meetings as well
as numerous networking opportunities. The conference is designed to foster an
informative dialogue between institutional investors and senior biotechnology
executives about emerging and current investment opportunities. Complimentary
registration is available to qualified institutional (buy and sell-side),
private equity, and venture investors and can be accessed here:
http://www.bio.org/events/conferences/bio-ceo-investor-registration.
Forward-looking information
This document may contain forward-looking statements and estimates with respect
to the anticipated future performance of TiGenix and the market in which it
operates. Certain of these statements, forecasts and estimates can be recognized
by the use of words such as, without limitation, "believes", "anticipates",
"expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties and other
factors, which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix' control. Therefore, actual results, the financial condition,
performance or achievements of TiGenix, or industry results, may turn out to be
materially different from any future results, performance or achievements
expressed or implied by such statements, forecasts and estimates. Given these
uncertainties, no representations are made as to the accuracy or fairness of
such forward-looking statements, forecasts and estimates. Furthermore, forward-
looking statements, forecasts and estimates only speak as of the date of the
publication of this document. TiGenix disclaims any obligation to update any
such forward-looking statement, forecast or estimates to reflect any change in
TiGenix' expectations with regard thereto, or any change in events, conditions
or circumstances on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.
For more information:
Eduardo Bravo
Chief Executive Officer
eduardo.bravo@tigenix.com
Claudia D'Augusta
Chief Financial Officer
claudia.daugusta@tigenix.com
Hans Herklots
hans.herklots@tigenix.com
+32 16 39 60 97
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via Thomson Reuters ONE
[HUG#1677094]